Sana Biotechnology (SANA) Return on Capital Employed (2021 - 2026)
Sana Biotechnology (SANA) reported Return on Capital Employed of 80.36% for Q1 2026, down 3205.0% on a YoY basis from 2.59% in Q1 2025, and down 11.54% sequentially from 72.05% in Q4 2025.
Sana Biotechnology (SANA) Return on Capital Employed (2021 - 2026) Analysis & Trends
Sana Biotechnology (SANA) has 6 years of Return on Capital Employed data on file, last reported at 80.36% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 3205.0% year-over-year to 80.36%; the trailing twelve-month figure through Mar 2026 stood at 80.36% (down 3205.0% YoY), and the FY2025 full-year result was 65.83%, down 992.0% from the prior year.
- Return on Capital Employed retreated to 80.36% in Q1 2026, from 72.05% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 20.89% in Q1 2022 to a low of 80.36% in Q1 2026.
- A 5-year average of 52.08% and a median of 54.91% in 2023 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed surged 2326 bps in 2022 and plunged 3205 bps in 2026, its largest moves.
- Tracing SANA's Return on Capital Employed over 5 years: stood at 36.39% in 2022, then sank by 51 bps to 54.91% in 2023, then dropped by 2 bps to 56.26% in 2024, then retreated by 28 bps to 72.05% in 2025, then dropped by 12 bps to 80.36% in 2026.
- Business Quant data shows SANA's Return on Capital Employed at 80.36% in Q1 2026, 72.05% in Q4 2025, and 66.11% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Sana Biotechnology | 888.71 Mn | 888.71 Mn | - | -80.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -80.36% |
| Dec 31, 2025 | -72.05% |
| Sep 30, 2025 | -66.11% |
| Jun 30, 2025 | -69.77% |
| Mar 31, 2025 | -48.31% |
| Dec 31, 2024 | -56.26% |
| Sep 30, 2024 | -57.65% |
| Jun 30, 2024 | -42.20% |
| Mar 31, 2024 | -56.06% |
| Dec 31, 2023 | -54.91% |
| Sep 30, 2023 | -47.18% |
| Jun 30, 2023 | -59.90% |
| Mar 31, 2023 | -47.64% |
| Dec 31, 2022 | -36.39% |
| Sep 30, 2022 | -36.85% |
| Jun 30, 2022 | -32.81% |
| Mar 31, 2022 | -20.89% |
| Dec 31, 2021 | -32.99% |
| Sep 30, 2021 | -31.10% |
| Jun 30, 2021 | -26.40% |